Method development and validation of Favipiravir by RP-HPLC

Main Article Content

Dr. Amit Suryakant Tapkir


Favipiravir (FVP) shows antiviral activity to tackle many viruses. It is very important for further analytical tests as a potential drug for COVID-19. A simple, accurate, precise, rapid, and gradient reverse phase high-performance liquid chromatography method developed for FVP pharmaceutical formulation. Analysis was carried out by Cosmosil C18 (250 mm × 4.6ID, Particle size: 5 micron). The mobile phase consisted of Methanol: Water (75:25, v/v). pH of Mobile Phase: 3 (pH is adjusted with o-phosphoric acid) The mobile phase was filtered and degassed through a 0.45 mm membrane filter before use and then pumped at a flow rate of 0.8 mL/min. The ultraviolet (UV) detection and column temperature were 227 nm, and 30°C. The retention time of FVP was found to be 4 min. The run time was 9 min under these chromatographic conditions. Linearity for FVP concentration 10–50 ppm has been observed with coefficient of determination of 0.9995. The recovery (%) was in the range of 98.94–99.12%, while the mean RSD (%) is 0.23%. The developed method was found to be sensitive (LOD and LOQ was found to be 0.2236 and 0.6776 resp.) Proposed method has been successfully applied for method development and validation of FVP in pharmaceutical formulations.


Download data is not yet available.

Article Details

How to Cite
Tapkir, D. A. S. . (2022). Method development and validation of Favipiravir by RP-HPLC. Innovative Journal of Medical Sciences, 6(2).
Original Articles